8-K: Verastem Initiates Rolling NDA Submission for Avutometinib and Defactinib Combination in Ovarian Cancer

Verastem has begun the rolling submission of a New Drug Application to the FDA for its combination therapy targeting recurrent low-grade serous ovarian cancer, while also providing updates on market opportunities and clinical trial data.

Summary

• Verastem has initiated a rolling submission of a New Drug Application (NDA) to the FDA for the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian cancer (LGSOC) with a KRAS mutation.
• The rolling review allows the FDA to review sections of the application as they are completed.
• The company is seeking accelerated approval and plans to request a priority review.
• The estimated total annual addressable market opportunity is approximately $300 million for KRAS mutant and $270 million for KRAS wild-type populations.
• The estimated total prevalent addressable market opportunity is approximately $1.7 billion for KRAS mutant and $1.1 billion for KRAS wild-type populations.
• These market estimates are based on an estimated annual incidence of 500 KRAS mutant and 1,000 KRAS wild-type patients, and a prevalence of 2,800 and 4,200 patients, respectively.
• The average duration of therapy is estimated at 18 months for KRAS mutant and 8 months for KRAS wild-type patients, with a cost of $34,000 per month.
• Interim data from the RAMP 201 trial shows a median duration of therapy of 14 months for KRAS mutant and 7 months for KRAS wild-type patients.
• Verastem also has a collaboration with GenFleet for up to three oncology programs, with a Phase 1/2 trial for a KRAS G12D inhibitor initiated in China.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting progress in regulatory submissions and market opportunities. However, it also acknowledges risks and uncertainties, which tempers the overall sentiment.

Positives

• The initiation of the rolling NDA submission is a significant step towards potential FDA approval.
• The company has received Orphan Drug and Breakthrough Therapy Designations for the combination therapy.
• There are currently no FDA-approved treatments specifically for recurrent LGSOC, presenting a significant market opportunity.
• The collaboration with GenFleet expands Verastem's pipeline with a KRAS G12D inhibitor.

Negatives

• The market estimates are based on internal and third-party assumptions that may be inaccurate.
• Interim clinical data may not be predictive of final results.
• The market opportunity could be smaller than estimated if the patient population is lower or if the approval is based on a narrower definition of the patient population.
• The company faces substantial competition in the oncology space.

Risks

• The success of the product candidates is subject to the uncertainties of research and development.
• Regulatory approvals are not guaranteed and may be delayed.
• The company may not be able to obtain adequate financing in the future.
• Clinical trial results may not be positive or may not support the scope of the NDA submission.
• The company may face manufacturing or supply interruptions.
• The market opportunities may be smaller than estimated.
• The company may not be able to successfully commercialize its product candidates.

Future Outlook

Verastem plans to continue the rolling NDA submission process, seek priority review, and advance its clinical programs, including the collaboration with GenFleet. The company also plans to seek the broadest label possible with mature RAMP 201 data.

Management Comments

• The Company plans to seek the broadest label possible with mature RAMP 201 data to inform final indication.
• Managements estimates of the patient population, pricing and revenue opportunities for the Companys product candidates, including KRAS mt and KRAS wt for patients with LGSOC, are based on a number of internal and third-party estimates.

Industry Context

The announcement is significant in the context of the oncology space, particularly for LGSOC, where there are currently no FDA-approved treatments. The development of targeted therapies like avutometinib and defactinib, and the KRAS G12D inhibitor, reflects a broader trend in precision medicine.

Comparison to Industry Standards

• The estimated cost of therapy at $34,000 per month is consistent with other recent oncology drug launches.
• The company is targeting a rare cancer with a specific genetic mutation, which is a common strategy in modern oncology drug development.
• The use of a rolling NDA submission is a common strategy to expedite the review process for promising therapies.
• The collaboration with GenFleet is similar to other partnerships between Western and Chinese biotech companies to expand market reach and access to innovative therapies.

Stakeholder Impact

• Shareholders may view the NDA submission and market opportunity estimates positively.
• Patients with LGSOC may benefit from a new treatment option.
• Employees may be motivated by the progress of the company's pipeline.
• The company's partners and collaborators may be encouraged by the progress.

Next Steps

• Continue the rolling NDA submission process with the FDA.
• Seek priority review of the NDA.
• Advance the RAMP 201, RAMP 205 and RAMP 301 clinical trials.
• Continue the collaboration with GenFleet and advance the Phase 1/2 trial in China.
• Seek the broadest label possible with mature RAMP 201 data.

Key Dates

Keywords

Avutometinib, Defactinib, LGSOC, Ovarian Cancer, KRAS, NDA, FDA, Oncology, GenFleet, Clinical Trial